Clinical Trial: Cancer

Renal Cancer BMSCA018- 005: A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Full Name

A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Description

  • Active Comparator: Nivolumab + Ipilimumab Nivolumab + Ipilimumab Interventions:
    • Biological: Nivolumab
    • Biological: Ipilimumab
  • Experimental: Nivolumab + BMS-986016 Nivolumab + BMS-986016 Interventions:
    • Biological: Nivolumab
    • Biological: BMS-986016

Eligibility

Inclusion Criteria
Inclusion Criteria:
  • Advanced Renal Cell Carcinoma
  • Must have at least 1 lesion with measurable disease
  • Life expectancy of at least 3 months

Exc

Exclusion Criteria
Exclusion Criteria:
  • Patients/subjects with suspected or known central nervous system metastases unless adequately treated
  • Patients/subjects with autoimmune disease
  • Patients/subjects who need daily oxygen therapy

Other protocol defined inclusion/exclusion criteria could apply

Doctor(s) Running This Study

Suresh G. Nair, MD

Specialties

  • Hematology/Medical Oncology

Area of focus i

  • Melanoma
  • Kidney cancer (renal cancer)
  • Sarcoma

Affiliated with

Make an Appointment

LVPG Cliniciani

Accepting New Patients

LocationPhone
LVH Hematology Oncology-1240 Cedar Crest

1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103-6218
United States

610-402-7880
LVH Hematology Oncology-1240 Cedar Crest

1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103-6218
United States

610-402-7880